Gabor Bethlendy

About Gabor Bethlendy

I build things before they have a name—across genomics, diagnostics, and now AI-driven infrastructure. Built the field collaborations that became CGH arrays, ChIP-chip, and oligo microarrays at Agilent, then genome enrichment at NimbleGen/Roche—product lines that grew to $200M+. Built the first rapid newborn sequencing platform (acquired by Quest Diagnostics), now saving tens of thousands of critically ill neonates. Created the first unified diagnostics marketplace at Meenta, scaled to $15M in revenue, including COVID testing for the U.S. Olympic Team. Currently building GRAVL—an infrastructure layer for scientific services and the structured “dark data” underlying research and pharma R&D. I operate across science, product, and commercialization—bringing platforms from concept to revenue, and through to clinical impact and exit. Typically brought in to scale, fix, or build businesses where the path isn’t yet obvious. Multilingual: English, Hungarian (native), Spanish (conversational).

Experience

1. Sr Advisor Life Sciences, Diagnostics, Healthtech

   Kairos Ventures

   Aug 2023 — Present · Boston, MA, US

Education

• Syracuse University

  Master, Family Therapy

  1992 — 1995

• University of Rochester

  Bachelor of Science - BS, Biochemistry

  1986 — 1990